The success of platinum-based anticancer agents has motivated the exploration of novel
metal-based drugs for several decades, whereas problems such as drug-resistance and …

Serum albumin, a natural ligand carrier that is highly concentrated and long-circulating in
the blood, has shown remarkable promise as a carrier for anti-cancer agents. Albumin is …

The demonstration in the 1960s that cis-diamminedichloroplatinum (II), or cisplatin, inhibits
cellular division of Escherichia coli 1 led to the subsequent discovery that this simple …

Albumin is the most abundant protein in human serum and drugs that are administered
intravenously inevitably interact with it. We present here a series of platinum (IV) prodrugs …

In this manuscript we focus on Pt (IV) anticancer prodrugs. We explore the main working
hypotheses for the design of effective Pt (IV) prodrugs and note the exceptions to the …

Drug resistance remains the major cause of cancer treatment failure especially at the late
stage of the disease. However, based on their versatile chemistry, metal and metalloid …

Platinum drugs comprise of almost 50% of all currently used anticancer drugs. They are now
widely used in the clinical therapy of various solid tumors, including ovarian, head and neck …

Neurotoxicity is a burdensome side effect of platinum-based chemotherapy that prevents
administration of the full efficacious dosage and often leads to treatment withdrawal …

Many international researchers have strived to understand the mechanism of action or
improve the efficacy of inorganic coordination compounds that have been identified to …

The design of targeted platinum (IV) prodrugs is a very promising approach to enhance the
low selectivity of platinum (II) drugs towards cancerous tissue in order to reduce the impact …